Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...

Read Our Latest Analysis on VERA Vera Therapeutics Stock Down 0.5 % The company has a market capitalization of $2.19 billion, a P/E ratio of -13.25 and a beta of 1.15. The company has a debt-to ...

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports.

BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...

Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...

Vera Therapeutics shares are trading lower by 7.3% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. Get Wall Street's Hottest Chart Every ...

Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on treatments for serious immunological diseases, announced that its management will present at the 43rd Annual J.P ...

Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement ...